Dynavax GmbH

Produktion: Multi-purpose production plant (GMP certification since 2003): Manufacturing of cell banks — aseptic formulation and filling — manufacturing of clinical test material — commercial production of recombinant biopharmaceuticals

Forschungsschwerpunkte: biopharmaceutical product development with special focus on vaccines, immunomodulators, adjuvants, biopharmaceutical particles

Services: Strain development — GMP cell banking — GLP strain characterization — process development (up- and downstream) — analytic development and validation — GLP/GMP analytics — scale-up and technology transfer — manufacturing of preclinical test material — formulation development — aseptic filling — GMP manufacturing of clinical test material — release of clinical test material — Immunology — Clinical Immunology

  • Mitarbeiterzahl

    80
  • Ausrichtungen
    • Lohnhersteller / Produzenten
  • Gegründet

    1985
  • Aktualisiert am

    13.12.2016